PARIS–(COMMERCIAL THREAD) – Iktos, a company specializing in artificial intelligence for the design of new drugs, today announced a collaboration agreement in the field of AI for the design of new drugs with Chiesi Group, the international group of pharmaceutical and health care research. Under the agreement, Iktos de novo Makya â¢ generative design software will be used by scientists at Chiesi to facilitate the rapid and cost-effective design of new compounds and accelerate hit-to-lead / lead optimization for Chiesi’s undisclosed drug discovery programs.
Iktos released Makya â¢, a generative AI-based software de novo Design software for multi-parametric optimization (MPO), available either as a SaaS platform or for implementation at the customer’s premises or in the customer’s virtual private cloud (VPC). Makya’s user-friendly interface allows it to be used by medicinal or computer chemists. Makya â¢ can also be used as a Python package through a Jupyter notebook interface.
Iktos’ AI technology, based on deep generative models, helps speed up and accelerate the drug discovery process, by automatically designing new virtual molecules that have the desired activities to treat a given disease. This addresses one of the main challenges in drug design: the rapid identification of molecules that simultaneously meet multiple bioactivity and drug-type criteria for drug discovery and development.
“The licensing of Makya is another step that Chiesi wanted to take in the digitization of R&D and in particular in drug discovery” said Maurizio Civelli, Head of Global Research and Preclinical Development Area of ââthe Chiesi GroupâThe opportunity to apply cutting-edge AI technology leveraging our internal expertise and historical data to drug design is very attractive. We believe this emerging technology will soon be part of the compound design toolkit for all medicinal chemists, to facilitate their work of identifying the right molecule â.
âWe are proud to work with Chiesi Farmaceutici, one of the 50 largest pharmaceutical companies in the world, and to see their scientists use our software in their early discovery programs,â said Yann Gaston-MathÃ©, Co-founder and CEO of Iktos. âOur ultimate goal is to put our technology in the hands of drug discovery scientists who have a deep knowledge and understanding of their discovery programs. By combining their expertise in drug discovery with our know-how and experience in algorithms and data science from the many collaborations we have established to date, we believe that AI’s promise to dramatically improve discovery of drugs will have a better chance of being realized and of having a therapeutic development impact â.
Founded in October 2016, Iktos is a start-up specializing in the development of artificial intelligence solutions applied to chemical research, more particularly to medicinal chemistry and the design of new drugs. Iktos is developing a proprietary and innovative solution based on generative deep learning models, which allows, from existing data, the design of molecules optimized in silico to meet all the criteria for the success of a small molecule discovery project. The use of Iktos technology allows significant productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both in the form of professional services and in the form of a SaaS software platform, Makya â¢. Iktos is also developing Spaya â¢, synthesis planning software based on Iktos proprietary AI technology for retrosynthesis.
More information on: http://www.iktos.ai/
About the Chiesi group
Based in Parma, Italy, Chiesi is an international research-driven pharmaceutical and healthcare group with over 85 years of experience, operating in 30 countries with over 6,000 employees (Chiesi Group). To fulfill its mission of improving people’s quality of life by acting responsibly towards society and the environment, the Group researches, develops and markets innovative therapeutic solutions in its three areas of intervention : AIR (products and services to promote breathing, newborn to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support specialized and self-care intended for consumers). The Group’s Research and Development center is based in Parma and works alongside six other major research and development centers in France, the United States, Canada, China, the United Kingdom and Sweden to continue its programs. preclinical, clinical and regulatory. In 2018, Chiesi changed its legal status to Benefit Corporation, in accordance with the law in Italy, the United States and, more recently, France, incorporating common benefit objectives in its articles, in order to generate value. for his business, for society and the environment. . Since 2019, Chiesi has been the largest B Corp certified pharmaceutical group in the world. B Corps is a global leader committed to using business as a force for good. In addition, as a social benefits company, Chiesi Farmaceutici SpA is required by law to report annually in a transparent manner on its progress in achieving the common benefit objectives that it has incorporated. The Group is committed to becoming carbon neutral by the end of 2035.
For more information: www.chiesi.com